SEC Form 4 · accession 0001140361-17-018529
BIOMARIN PHARMACEUTICAL INC · BMRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey Robert Ajer
Officer — EVP, Chief Commercial Officer
Period of report
May 2, 2017
Accepted (ET)
May 4, 2017 · 8:54 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001048477
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Apr 28, 2017 | A | 302 | $70.304 | A | 51,834 | D | |
| Common StockF2,F3 | May 2, 2017 | S | 302 | $96.74 | D | 51,532 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents shares acquired by the reporting person pursuant to the issuer's Employee Stock Purchase Plan
- F2Trade made pursuant to a 10b5-1 plan executed on August 18, 2016.
- F3All shares were sold at the same price.